Oncology Partnerships Vault Pharma's vault particle platform delivers potent antigen-specific CD4 and CD8 T cell responses with a non-inflammatory profile, presenting a compelling option for cancer immunotherapy collaborations. Potential sales opportunities include licensing the platform or forging co-development deals with mid-to-large biotechs seeking novel immune payload delivery to boost tumor targeting and TIL activity.

Off-the-Shelf Edge Vaults are non-immunogenic, identical across individuals, and highly scalable, enabling off-the-shelf therapeutic applications. This can appeal to product teams seeking readily deployable immunotherapy payloads, reducing development timelines and regulatory risk, with opportunities for upfront licensing or milestone-based revenue.

Preclinical Collaborations Animal and cell model data show enhanced tumor-infiltrating lymphocyte responses and reduction of immune suppressive factors, creating a strong case for sponsored preclinical studies, platform validation collaborations, or CRO partnerships to accelerate IND timelines.

Strategic Partnerships Leadership with a proven track record in commercialization of cellular therapies combined with a lean team signals readiness for strategic partnerships or licensing with larger biotechs seeking platform expansion. Opportunities include milestone-based payments, co-development, exclusive regional rights, or supply agreements.

Market Positioning Position Vault Pharma as a versatile immunotherapy platform provider for oncology and immune modulation, emphasizing safety, stability, and scalable production. Target outreach to biotech accelerators, KOLs, early-stage investors, and potential acquirers to build a robust partner and revenue pipeline.